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In the past decade, novel methods using engineered receptors have enabled researchers to manipulate neuronal activity with increased
spatial and temporal specificity. One widely used chemogenetic method in mice and rats is the DREADD (designer receptors exclusively
activated by designer drugs) system in which a mutated muscarinic G protein-coupled receptor is activated by an otherwise inert synthetic
ligand, clozapine-N-oxide (CNO). Recently, the Roth laboratory developed a novel inhibitory DREADD in which a mutated kappa-opioid
receptor (KORD) is activated by the pharmacologically inert drug salvinorin B (SalB; Vardy et al, 2015). They demonstrated the feasibility of
using KORD to study brain circuits involved in motivated behavior in mice. Here, we used behavioral, electrophysiological, and
neuroanatomical methods to demonstrate the feasibility of using the novel KORD to study brain circuits involved in motivated behavior in
rats. In Exp. 1, we show that SalB dose-dependently decreased spontaneous and cocaine-induced locomotor activity in rats expressing
KORD to midbrain (ventral tegmental area/substantia nigra). In Exp. 2, we show that SalB completely inhibited tonic firing in KORD-
expressing putative dopamine neurons in midbrain. In Exp. 3, we used a ‘retro-DREADD’ dual-virus approach to restrict expression of
KORD in ventral subiculum neurons that project to nucleus accumbens shell. We show that KORD activation selectively decreased novel
context-induced Fos expression in this projection. Our results indicate that the novel KORD is a promising tool to selectively inactivate
brain areas and neural circuits in rat studies of motivated behavior.
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INTRODUCTION
In the past decade, several novel optogenetic and chemoge-
netic techniques using engineered receptors have enabled
researchers to manipulate neuronal activity with increased
spatial and temporal specificity (Boyden et al, 2005;
Armbruster et al, 2007). Chemogenetics refers to the
approach of using engineered receptors that can inhibit
(Armbruster et al, 2007) or activate (Alexander et al, 2009)
neurons when an otherwise inert ligand binds to them
(Urban and Roth, 2015). DREADDs (designer receptors
exclusively activated by designer drugs) are chemogenetic
tools with therapeutic utility (Urban and Roth, 2015) and
have been used to manipulate cell signaling within diverse
cell types (Rogan and Roth, 2011). However, the dependency
on the same chemical actuator clozapine-N-oxide (CNO) has
restricted the ability to use DREADDs to selectively either
inhibit or activate neuronal activity in the same animal.
Recently, the Roth laboratory developed a novel DREADD
that is based on the Gi-coupled kappa-opioid receptor
(KORD) and the pharmacologically inert ligand is salvinorin
B (SalB) (Vardy et al, 2015). SalB is a metabolite of the KOR
selective agonist salvinorin A (SalA) that has minimal or no
affinity to KOR and numerous other receptors, as assessed in
receptor binding assays (Roth et al, 2002; Ansonoff et al,
2006). SalB also has minimal or no observed behavioral
effects in mice under conditions in which SalA is highly
effective (eg, increases in brain stimulation threshold)
(Vardy et al, 2015). In the paper describing the development
and validation of KORD, Vardy et al used mice to show that
KORD-mediated inhibition of ventral tegmental area (VTA)
GABAergic neurons dose-dependently increased locomo-
tion, and that KORD-mediated inhibition of hypothalamic
arcuate nucleus Agouti-Related Peptide (AgRP) decreased
food intake, whereas paraventricular SIM1 neuron inhibition
increased food intake. These studies show that KORD is
effective at changing certain behaviors in mice. Here, we
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validate the use of KORD in rats because our goal is to
eventually use KORDs in circuitry-related studies that
control appetitive and aversive motivated behaviors, studies
that cannot be performed or are very difficult to perform in
mice (see Discussion).
Here, we demonstrate the feasibility of KORD as a tool to
study brain circuits of motivated behaviors in rats using
behavioral, electrophysiological, and neuroanatomical ap-
proaches. We show that SalB dose-dependently decreased
spontaneous and cocaine-induced locomotor activity in
rats expressing KORD in midbrain. We also show that SalB
inhibited tonic firing in KORD-expressing putative dopa-
mine neurons in midbrain. These effects were selective for
the specific combination of DREADD and ligand, because
SalB had no apparent effect on locomotor activity or
neuronal firing in rats bilaterally injected with the Gi/o-
DREADD hM4Di. In addition, we describe a dual-virus
method to restrict DREADD expression to projection
neurons in long-range circuits (Boender et al, 2014; Nair
et al, 2013; Rothermel et al, 2013; Friedman et al, 2014) that
we term herein ‘retro-DREADD.’ Using novel context
exposure to increase neural activity, indexed by Fos
expression (Morgan and Curran, 1991), we show that SalB
decreased Fos expression in ventral subiculum neurons that
project to nucleus accumbens shell (Groenewegen et al, 1987;
Pennartz et al, 1994). These data demonstrate the ability
of KORD to inhibit neural activity in vivo, in a projection-
specific manner, in rats. This method may be especially
useful for investigators interested in studying the causal role
of defined neural projections in complicated behaviors where
the experimental subjects are rats.
MATERIALS AND METHODS
Subjects
We used male Sprague-Dawley rats (Charles River or NIDA
breeding core, n= 49) weighing 250–450 g before surgery.
The rats in the electrophysiology experiment were previously
tested in the locomotor activity experiments. We maintained
the rats under a reverse 12 : 12 h light/dark cycle with food
and water freely available. We housed the rats two per cage
before and after surgery. We performed the experiments in
accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals (8th edition) under
protocols approved by the Animal Care and Use Committee.
We excluded seven rats due to unilateral, low, or no virus
expression.
Viral Injection Surgery
We anesthetized the rats with ketamine and xylazine (80 and
10 mg/kg, i.p., respectively) and used 10 μl microinjection
syringes (Hamilton syringe or Nanofil from World Precision
Instruments) with 33 gauge needles secured to stereotaxic
pumps (UMP4 injector; World Precision Instruments). We
set the nose bar at − 3.3 mm. In Exp. 1 and 2, we bilaterally
injected AAV9.CaMKIIa.HA-KORD.IRES.mCitrine (AAV-
KORD; titer 3.0 × 1012 gc/ml; synthesized by BR and EV,
UNC vector core) or AAV1.CamKIIa.HA-hM4D(Gi).IRES.
mCitrine (AAV-hM4Di; titer 1.39 × 1012 gc/ml; synthesized
by BH, OTTC, IRP-NIDA) into VTA/substantia nigra
(midbrain) using the following coordinates from Bregma
(Paxinos and Watson, 2008): AP: − 5.2 mm; ML: ± 3.0 mm
(10° angle); and DV: − 8.5 mm.
In Exp. 3, we unilaterally injected AAV5.CMV.HI.eGFP-
Cre.WPRE.SV40 (AAV-Cre; titer 8.56 × 1012 gc/ml; UPenn
vector core) into nucleus accumbens shell (AP: +1.6 mm,
ML: ± 2.3 mm (10° angle), DV: − 7.5 mm) and unilaterally
injected AAV9.SYN1.dF.HA.KORD.IRES.mCitrine (AAV-
DIO-KORD; titer 1.2 × 1013 gc/ml; synthesized by BR and
EV, UNC vector core) into ipsilateral ventral subiculum
(AP: − 6.0 mm, ML: ± 5.3 mm (4º angle), DV: − 8.5 mm).
These coordinates are based on our previous studies (Bossert
et al, 2004, 2012; Bossert and Stern, 2014).
For all surgeries, we injected 0.75 μl of the virus solution
per side at a rate of 0.25 μl/min over 3 min and we left the
microinjector needles in place for 1 min before removing
them. We then placed bonewax (Butler Schein) over the
holes, sutured the wounds, and removed the rats from the
stereotaxic frame. We injected rats with 3 ml sterile 0.9%
saline (s.c.) to prevent dehydration and injected rats with
the NSAID ketoprofen (2.5 mg/kg, s.c.) immediately after
surgery and the day after surgery to reduce inflammation.
We handled the rats three times per week before the start of
the locomotor tests (began 212–3 weeks after surgery) or
before the homecage vs novel context exposure (6 weeks after
surgery).
Drugs
We obtained (− )-cocaine hydrochloride (dissolved in sterile
saline) from NIDA and injected it at a dose of 10 mg/kg
(i.p.). Salvinorin B (SalB) was synthesized in the laboratory
of Thomas E. Prisinzano at the University of Kansas, as
described previously (Tidgewell et al, 2004) and dissolved
in 100% DMSO at doses of 0, 7.5, 15, and 30 mg/kg (s.c.).
We chose these doses based on the recent mouse study
(Vardy et al, 2015) and on a pilot experiment in which
we determined that these doses of SalB had no effect on
spontaneous locomotion and cocaine-induced locomotion
in rats not injected with virus (data not shown). We obtained
CNO from the NIH Investigative Drug Program and
dissolved it in 5% DMSO in sterile water. We injected
it at a dose of 3 mg/kg (i.p.). This dose is based on the
previous reports (Ferguson et al, 2011, 2013; Nair et al,
2013).
Specific Experiments
Exp. 1: Behavioral Validation of KORD. We tested
whether SalB would decrease spontaneous and cocaine-
induced locomotor activity in rats (n= 8) injected bilaterally
with AAV-KORD into midbrain (Figure 1a). For this
purpose, we used an experimental design that included the
within-subject factors of SalB Dose (0 (DMSO), 7.5, 15, and
30 mg/kg) and Cocaine Dose (0 (saline), 10 mg/kg). We used
locomotor chambers (Accuscan Instruments; 42 ×42 ×
30 cm3) and collected data in 5-min intervals using the
VersaMax version 3.0 data analysis system (Accuscan
Instruments). We used total distance traveled to evaluate
the effect of SalB on spontaneous and cocaine-induced
locomotor activity. We first placed the rats in the locomotor
boxes for 30 min. We then injected them with the SalB dose
and 10 min later we injected them with either saline or
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cocaine and measured locomotor activity for 30 min; we
counterbalanced the order of the injections of the different
doses of SalB and saline/cocaine during the 4-test daily test
sessions.
To determine selectivity of SalB to KORD, we also mea-
sured spontaneous and cocaine-induced locomotor activity
in rats (n= 11) injected with AAV-hM4Di into midbrain; we
chose this virus as the control condition because its other
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Figure 1 Effect of Salvinorin B on locomotor activity and putative dopamine cell firing in rats expressing KORD in midbrain. (a) Top: Timeline of the
locomotor experiment. Bottom: Mean± SEM total distance in meters in rats expressing either KORD (left; n= 8) or hM4D (right; n= 11) in midbrain.
*Different from vehicle in the Cocaine condition, Po0.05; #Different from vehicle in the Saline condition, Po0.05. (b) Representative images of bilateral
KORD (native mCitrine) expression in midbrain. Scale= 200 μm. VTA, ventral tegmental area; SN, substantia nigra. (c) Top: Firing rate (Hz) of putative
midbrain dopamine neurons expressing either KORD (2 rats, 5 neurons) or hM4i-DREADD (3 rats, 10 neurons) after administration of vehicle or SalB
(100 nM). *Different from the other experimental conditions, Po0.05. Bottom: Time course from an example experiment in which SalB inhibited tonic firing in
a single putative dopamine neuron. Firing returned to baseline rate after drug washout. (d) Example traces from KORD-expressing neurons after vehicle and
SalB bath application.
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components (CamKIIa, IRES, and mCitrine) are similar to
those of AAV-KORD (albeit with different serotypes). We
evaluated the effect of SalB on locomotor activity using an
experimental design that included the within-subject factors
of SalB Dose (0, 30 mg/kg) and Cocaine Dose (0, 10 mg/kg).
Finally, we repeated the experiment in most of the rats
(n= 9) where we injected vehicle or CNO (3mg/kg, i.p.)
30 min before saline or cocaine injections during four daily
locomotor activity sessions.
To verify expression of KORD in midbrain, we deeply
anesthetized three AAV-KORD-injected rats (the other rats
were used in Exp. 2) with isoflurane (approximately 90 s)
and perfused them transcardially with 100 ml of 0.1M
phosphate-buffered saline (PBS) followed by 400 ml of 4%
paraformaldehyde (PFA) in 0.1M sodium phosphate (pH
7.4). We removed the brains and post-fixed them in 4% PFA
for 2 h before we transferred them to 30% sucrose in 0.1M
sodium phosphate (pH 7.4) for 48 h at 4 °C. We subsequently
froze the brains in powdered dry ice and used a cryostat
to collect coronal sections (40 μm) containing midbrain
(approximately − 4.8 to − 5.6 mm from Bregma) in 0.1%
sodium azide. We digitally captured dark-field images of
native mCitrine fluorescence in the midbrain using an EXi
Aqua camera (QImaging) attached to a Zeiss Axio Scope 2,
Axio Imager M2. We captured and analyzed the images
using iVision (Biovision).
Exp. 2: Electrophysiological Validation of KORD. The
electrophysiology of this procedure is based on a previous
study (Whitaker et al, 2013). At least 3 days after the rats
completed the locomotor activity experiments, we deeply
anesthetized them with isoflurane (60–90 s) and then rapidly
decaptitated them. We cut horizontal midbrain slices in ice-
cold solution containing (in mM) 92 NMDG, 20 HEPES, 25
Glucose, 30 NaHCO3, 1.2 NaH2PO4, 2.5 KCl, 5 Na-ascorbate,
3 Na-pyruvate, 2 Thiourea, 10 MgSO4, 0.5 CaCl2, saturated
with 95% O2 5% CO2 (pH 7.3–7.4, ~ 305 mOsm/kg ). We
then incubated the slices for 5 min at 35 °C in the same
solution. We allowed the slices to recover for a minimum of
30 min at room temperature in artificial cerebrospinal fluid
(ACSF) containing (in mM) 126 NaCl, 2.5 KCl, 1.2 MgCl2,
2.4 CaCl2, 1.2 NaH2PO4, 21.4 NaHCO3, 11.1 Glucose, 3 Na-
pyruvate, and 1 Na-ascorbate. We performed the recordings
at 32–35 °C in the same solution after adding 50 μM
picrotoxin (to block GABAA receptors), which was bath-
perfused at 2 ml/min. Intracellular solution contained
(in mM) 115 K-gluconate, 20 KCl, 1.5 MgCl2, 10 HEPES,
0.025 EGTA, 2 Mg-ATP, 0.2 Na2-GTP, 10 Na2-phospho-
creatine (pH 7.2–7.3, ~ 285 mOsm/kg).
We identified DREADD-expressing (mCitrine-positive)
neurons using a scanning disk confocal microscopy (Olym-
pus FV1000) and used differential interference contrast
optics to patch neurons. We performed whole-cell record-
ings in electrophysiologically identified putative dopamine
neurons of midbrain pars compacta in zero current mode
(Grace, 1988; Morikawa et al, 2003; Ungless and Grace,
2012). We identified putative dopamine neurons by their
spontaneous firing (0.5–5 Hz) with broad APs (41.2 ms)
and large Ih currents (4200 pA elicited by 1.5 s hyperpolari-
zing step from − 60 mV to − 110 mV) recorded in whole-cell
configuration (Whitaker et al, 2013). We discarded recording
if the series resistance change was 410% during the course
of the recording, or if input resistance fell below 180MΩ. We
used an Axopatch 200B amplifier (Molecular Devices) and
Axograph X software (Axograph Scientific) to record and
collect the data, which we filtered at 2–10 kHz and digitized
at 4–20 kHz.
We applied SalB (100 nM) and CNO (10 μM) by super-
fusion to the slice (Krashes et al, 2011; Vardy et al, 2015).
For AAV-KORD-injected rats, each recording session
started with 5–10 min of baseline recording, following
by superfusion of vehicle (DMSO) for 5–10 min, and SalB
for 5–10 min. For 2 hM4Di-injected rats (6 neurons), we
followed the same procedure, but after SalB perfusion,
we also superfused CNO for 5–10 min, followed by a 10- to
20-min washout period.
Exp. 3: Immunohistochemical Validation of KORD in
Combination with ‘retro-DREADD’. We tested whether
SalB would inhibit novel context-induced Fos in ventral
subiculum neurons that project to nucleus accumbens
shell. For this purpose, we used four groups of rats injected
with AAV-Cre into nucleus accumbens shell and AAV-DIO-
KORD in ventral subiculum. We used a 2 × 2 factorial design
that includes the between-subject factors of Context (home,
novel) and SalB Dose (0 (vehicle), 15 mg/kg). Six weeks after
surgery, we injected rats with vehicle or 15 mg/kg SalB and
placed them in their homecage or a novel context (large
round plastic bowel with bedding and toys). We returned the
novel context rats to their homecage after 30 min because the
effect of SalB on locomotor activity in mice lasts for less than
60 min (Vardy et al, 2015).
Ninety minutes after vehicle or SalB injection, we
deeply anesthetized the rats with isoflurane (approximately
90 s) and perfused them transcardially with 100 ml of 0.1M
PBS followed by 400ml of 4% PFA in 0.1M sodium
phosphate (pH 7.4). We removed the brains and post-fixed
them in 4% PFA for 2 h before we transferred them to 30%
sucrose in 0.1M sodium phosphate (pH 7.4) for 48 h at 4 °C.
We subsequently froze the brains in powdered dry ice and
used a cryostat to collect coronal sections (40 μm) containing
nucleus accumbens shell (approximately +2.0 to +1.0 mm
from Bregma) and ventral subiculum (approximately − 5.4 to
− 6.4 mm from Bregma) in 0.1% sodium azide.
We rinsed free-floating sections three times for 10 min
each in PBS, incubated for 2 h in 4% bovine serum albumin
(BSA) in PBS with 0.4% Triton X-100 (PBS-Tx), and
incubated overnight at 4 °C with rabbit anti-Fos monoclonal
primary antibody (Phospho-c-Fos, 5348S, Cell Signaling)
diluted 1 : 2000 and mouse anti-HA monoclonal primary
antibody (HA.11 clone 16B12, MMS-101R, Covance) diluted
1 : 1000 in 4% BSA in PBS-Tx. We then rinsed sections in
PBS and incubated for 2 h with AF 594 anti-rabbit secondary
antibody (711-585-152, Jackson Immunoresearch) and AF
488 anti-mouse secondary antibody (A-11001, Invitrogen)
diluted 1 : 500 in 4% BSA in 0.4% PBS-Tx. We then rinsed
the sections again, mounted the tissue onto gelatin-coated
slides, and coverslipped with Vectashield Hardset Mounting
Medium (H-1400, Vector Labs).
We digitally captured dark-field images of native Cre-GFP
fluorescence in nucleus accumbens shell and double labeling
of Fos and HA (a tag fused to the KORD, here referred to as
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KORD) in ventral subiculum using an EXi Aqua camera
attached to a Zeiss Axio Scope 2, Axio Imager M2 and
analyzed the images using iVision (Biovision) in a double-
blind manner. We counted the number of Fos-immuno-
reactivity (IR), KORD-IR, and double-labeled (Fos+KORD)
cells from three injected hemispheres of ventral subi-
culum and used the mean of the counts for the statistical
analysis.
Statistical Analyses
Locomotor activity. We analyzed the data with the SPSS
statistical software (IBM) using repeated measures ANOVA:
within-subject factors of SalB dose (0, 7.5, 15, and 30mg/kg
for KORD, or 0 and 30 mg/kg for hM4Di) or CNO dose
(0 and 3mg/kg for hM4Di) and cocaine dose (0 and
10 mg/kg). We followed-up on significant effects (Po0.05)
using the Fisher PLSD post hoc test.
Electrophysiology. The n in the analysis was the total
number of neurons and the dependent measure was firing
rate of putative dopamine neurons in midbrain. We analyzed
the data using the between-subject factor of Virus Condition
(KORD, hM4Di) and the within-subject factor of SalB
Concentration (0, 100 nM).
Fos-IR, KORD-IR, and Fos+KORD Double-IR. We ana-
lyzed the data with factorial ANOVA using the between-
subject factors of SalB dose (0, 15 mg/kg) and context
(Homecage, Novel).
RESULTS
Exp. 1: Effect of SalB on Locomotor Activity in Rats
Expressing KORD or hM4Di in Midbrain
SalB dose-dependently decreased both spontaneous (saline
injections) and cocaine-induced locomotor activity in
KORD-expressing rats (Figure 1a). The analysis showed
significant main effects of SalB Dose (F(1,7)= 36.9, Po0.01)
and Cocaine Dose (F(1,7)= 5.8, Po0.05), and an approaching
significant interaction between the two factors (F(1,7)= 4.2,
P= 0.08). The approaching significant interaction effect is
due to the somewhat stronger inhibition of locomotor
activity in the cocaine vs the saline condition. In contrast,
SalB (30 mg/kg) had no effect on spontaneous or cocaine-
induced locomotor activity in hM4Di-expressing rats
(Figure 1a). The analysis showed a significant main effect
for Cocaine Dose (F(1,10)= 32.6, Po0.01) but not SalB Dose
(P40.1) or an interaction between these two factors
(P40.1). CNO (3mg/kg) decreased both spontaneous
(saline injections) and cocaine-induced locomotor activity
in hM4Di-expressing rats (Table 1). The analysis showed
significant main effects of CNO Dose (F(1,7)= 13.0, Po0.01)
and Cocaine Dose (F(1,7)= 48.8, Po0.01), and a significant
interaction between CNO Dose and Cocaine Dose
(F(1,7)= 10.9, Po0.05). The significant interaction is due to
the stronger inhibition of locomotor activity in the cocaine vs
the saline condition.
Exp. 2: Effect of SalB on Firing Rate of Putative
Dopamine Neurons in Midbrain
SalB completely inhibited cell firing in KORD-expressing but
not in hM4Di-expressing putative dopamine neurons
(identified by mCitrine fluorescence) (Figures 1b–d). The
statistical analysis, which included 5 KORD expressing
neurons and 10 hM4Di expressing neurons, showed a
significant interaction between Virus Condition and SalB
Concentration (F(1,13)= 14.8, Po0.01). Additionally, SalB
completely inhibited (100%) cell firing of three KORD-
infected neurons in which we did not assess the vehicle
condition. Finally, in rats expressing hM4Di in midbrain,
bath application of CNO (10 μM, n= 2, 6 neurons) decreased
baseline firing rate by 97.8%.
The in vitro data suggest that KORD activation can
suppress neural activity for approximately 15 min after SalB
application (Figure 1c). Additionally, our informal observa-
tions of the rats at the end of the locomotor tests were that
their locomotor behavior was still suppressed at the end of
the session. This suggests that the action of SalB in vivo lasts
for at least 30 min.
Exp. 3: Effect of SalB on Novel Context-Induced Fos
Expression in Ventral Subiculum Neurons that Project
to Nucleus Accumbens Shell
We observed robust expression of KORD (KORD-IR) in
ventral subiculum in rats injected with AAV-Cre into
nucleus accumbens shell and AAV-DIO-KORD into ventral
subiculum (Figure 2b). This observation demonstrates that
the AAV-Cre virus infected ventral subiculum terminals in
nucleus accumbens shell, which was then transported back to
the cell bodies in ventral subiculum. The statistical analysis
showed no differences in KORD-IR between the four groups
(P40.05) (Figure 2c).
SalB injections decreased neuronal activity (as assessed by
Fos-IR) in ventral subiculum (Figure 2d). More importantly,
these injections also decreased neuronal activity in neurons
projecting to nucleus accumbens shell (as assessed by
double-labeling of Fos-IR with KORD-IR) (Figure 2e). The
analysis of Fos-IR showed a significant interaction between
SalB Dose and Context (F(1,19)= 13.4, Po0.01). The analysis
of the double-labeling of Fos-IR with KORD-IR showed
main effects for SalB Dose (F(1,19)= 26.6, Po0.01) and
Context (F(1,19)= 7.4, Po0.05), but no interaction between
the two factors (P40.1) (Figure 2e). The lack of significant
interaction illustrates that SalB decreased Fos-IR in KORD-
IR neurons in both the home-cage and novel context
conditions.
Table 1 Effect of CNO on Spontaneous and Cocaine-Induced
Locomotor Activity in Rats Expressing AAV-hM4Di in the Midbrain
Saline Cocaine (10mg/kg)
Vehicle 28± 0.3 158± 26
CNO (3 mg/kg) 17± 0.3* 64± 15*
Data are mean± SEM of meters per 30 min (n= 9). *Different from the CNO
condition, Po0.05.
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DISCUSSION
We report three main findings. First, we found that SalB
dose-dependently decreased spontaneous and cocaine-
induced locomotor activity in rats with KORD expression
in midbrain. The effect of SalB on locomotion was selective
to KORD-expressing rats as there was no effect of SalB on
locomotor activity in rats expressing the Gi/o-DREADD
hM4Di in midbrain. Second, we found that SalB completely
inhibited cell firing in KORD, but not in hM4Di, expressing
neurons. Third, using a ‘retro-DREADD’ approach (Boender
et al, 2014), we showed that SalB decreased novel context-
induced Fos expression in ventral subiculum neurons
projecting to nucleus accumbens shell. This observation
demonstrates that KORD expression can be restricted to
neurons defined by the projection target, and that these
neurons can be inhibited in vivo with systemic injections of
SalB. This demonstration illustrates the feasibility of using
this retro-DREADD approach to study the role of neural
circuits in complicated behavioral studies in rats.
Our finding that SalB decreases cocaine-induced loco-
motor activity in rats expressing KORD in midbrain is
consistent with early findings showing that inhibition
of the nigrostriatal dopaminergic system decreases psycho-
stimulant-induced motor behaviors (Fibiger et al, 1973;
Creese and Iversen, 1975). Our results demonstrate that
KORD activation is sufficient to overcome the significant
level of behavioral activation induced by cocaine, which
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illustrates the potent effect of KORD activation has to inhibit
neuronal activity.
We also showed, using electrophysiology and immuno-
histochemistry methods, that SalB action on KORD inhibits
ex vivo spontaneous action potentials and Fos expression.
Additionally, we showed that SalB does not interact with
the muscarinic-based DREADD hM4Di in vivo, which is
consistent with prior in vitro studies in mice (Vardy et al,
2015). Thus, in the same rat KORD can be used in combi-
nation with the muscarinic-based DREADDs (either hM4Di
or hM3Dq) to either selectively inhibit two different cell
types or neuronal projections (combination of KORD and
hM4Di), or to selectively inhibit or excite two different cell
types or neuronal projections (combination of KORD and
hM3Dq). KORD and hM3Dq can also potentially be used
together to inhibit and excite the same cell type or neuronal
projection in the same rat, as was demonstrated in mice
(Vardy et al, 2015).
Our data provide evidence for restricted expression of
Cre-dependent KORD in projection neurons using a retro-
grade AAV encoding Cre. There is evidence in the literature
that certain AAV serotypes have properties that facilitate
retrograde transport (Aschauer et al, 2013; Rothermel et al,
2013). The efficiency of retrograde transport is an important
consideration in ‘Retro-DREADD’ studies. Aschauer et al
(2013) provided evidence for complete overlap between
neurons that were retrograde labeled with AAV and
traditional retrograde tracers (cholera toxin b subunit:
CTb); however, the total number of AAV-labeled neurons
was lower than CTb labeled. Interestingly, we found that the
total number of KORD expressing neurons in ventral subi-
culum was similar to the total number of retrograde
labeled neurons identified in ventral subiculum after
injections of traditional retrograde tracers, such as CTb or
Fluoro-Gold, in nucleus accumbens shell (Marchant, Bossert,
unpublished data).
We also provided functional evidence of projection-specific
inhibition of neurons using KORD. We found that SalB
decreased novel context-induced Fos in ventral subiculum
neurons that project to nucleus accumbens shell in rats injected
with AAV-Cre into nucleus accumbens shell and AAV-DIO-
KORD into ventral subiculum. The ventral subiculum sends a
strong glutamatergic projection to nucleus accumbens shell
(Groenewegen et al, 1987) and hippocampal and tyrosine
hydroxylase-labeled terminals in the accumbens converge on
the same postsynaptic dendrites (Sesack and Pickel, 1990). We
chose to study this particular pathway in the current study
because we have shown that both nucleus accumbens shell and
ventral subiculum are independently important for context-
induced reinstatement of heroin seeking in our relapse studies
(Bossert et al, 2007; Bossert and Stern, 2014).
The current finding suggests that the retro-DREADD
dual-virus approach described in our study is suitable for
selective projection silencing in studies on circuits control-
ling appetitive and aversive motivated behaviors in rats.
These are studies that cannot be performed or are very
difficult to perform in mice. For example, our retro-
DREADD method is ideally suitable for circuitry-related
studies using long-term intravenous drug self-administration
procedures (Schuster and Thompson, 1969) and animal
models of drug relapse and craving (Shaham et al, 2003;
Pickens et al, 2011) that are technically challenging in mice.
The new retro-DREADD method can also be used by
investigators who study brain circuits of learning and
memory, as assessed in complex learning tasks in rats
(Holland and Bouton, 1999; Pearce and Bouton, 2001;
Schoenbaum et al, 2009). Additionally, KORDs can be
used in combination with the original muscarinic-based
DREADDs to permit bi-directional control over either the
same or different neural projections as described in Vardy
et al (2015). Finally, the dual-virus approach is versatile; one
could replace the DIO-KORD construct with other Cre-
dependent viruses (eg, Tian et al, 2012; Yang et al, 2013) to
monitor and manipulate neural projections during complex
behaviors in rats.
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